This trial will test a new treatment for achromatopsia, a condition that causes decreased color vision. The study will measure the safety and effectiveness of the new treatment.
AGTC-402 is a drug that is used to treat Achromatopsia, and it has been approved by the FDA for a different condition in the past. There will be no placebo given to any of the patients in this trial, and the treatment will be free of charge.
Phase 1 & 2